Thursday’s Pre-Market Insights: GoPro Inc (GPRO), NeoStem Inc (NBS), Valeant Pharmaceuticals Intl (VRX), International, Ltd. (ADR)(CTRP)

GoPro Inc (NASDAQ:GPRO) shares increased +2.63% in pre-market trading to $54.68 after CEO Nick Woodman unveiled GoPro’s virtual reality system at the Code tech conference yesterday in California. The product will be comprised of six cameras and will be available in the second half of the year, though prices have yet to be announced. According to, the 12-month consensus target price on the stock is $69.83, showing a return potential of 31.06% based on the current stock trading price. Out of 27 analysts who cover GoPro stock, 15 gave it a Buy rating, and 5 recommended a Hold.

NeoStem Inc (NASDAQ:NBS) shares fell more than -22% in pre-market trading to $2.05 after the biopharmaceutical company announced an underwritten public offering of 12.5 million shares of common stock at $2.00 per share. NeoStem will use capital for research and development, strategic transactions, and other relevant corporate purposes. Out of the 3 analysts polled by TipRanks, 3 rate NeoStem stock a Buy. With a return potential of 280.23%, the stock’s 12-month consensus target price stands at $10.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) shares increased more than 2% to $244.26 after they received FDA approval for Xifaxan; a drug for irritable bowel syndrome in adults. The Canadian biopharmaceutical company acquired the drug after it purchased Salix Pharmaceuticals. According to Tipranks, there are five analysts with Buy ratings on VRX and one with a Sell. International, Ltd. (ADR) (NASDAQ:CTRP) shares fell 2.86% to $79.18 in pre-market trading after the Chinese online travel company was hacked. The hack disturbed the website and mobile services but customer reservation data has not been harmed. According to TipRanks, eight analysts have a Buy rating on the stock and none have a Hold or Sell rating.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts